Why Tilray Stock Dropped This Week, Even After President Trump's Executive Order

Group 1 - The cannabis sector experienced significant activity due to rumors of President Trump's plan to reclassify marijuana from Schedule I to Schedule III, leading to a surge in pot stock shares [1] - Tilray Brands (NASDAQ: TLRY) saw its stock rise by 28% at its peak during the week, but ultimately lost all gains, ending the week down 7.4% [2] - The executive order signed by President Trump primarily aimed at improving access to medical marijuana and CBD products, which is expected to benefit Tilray's business, though not as significantly as broader recreational marijuana legalization would have [4][6] Group 2 - Tilray announced plans to accelerate its U.S. medical cannabis operations following the executive order, with CEO Irwin Simon expressing support for the decision as a necessary evolution of federal policy [5] - The CEO described the executive order as an incremental step toward legalization, which raises concerns for investors about its immediate impact on Tilray's business [6] - Analysts from The Motley Fool Stock Advisor have identified ten stocks they believe are better investment opportunities than Tilray Brands, indicating a lack of confidence in Tilray's potential for significant returns in the near future [7][8]